Creative Planning Increases Position in Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Creative Planning boosted its stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) by 3.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 173,475 shares of the biopharmaceutical company’s stock after buying an additional 6,525 shares during the period. Creative Planning owned 0.35% of Corbus Pharmaceuticals Holdings worth $1,093,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Corbus Pharmaceuticals Holdings by 16.5% in the first quarter. Geode Capital Management LLC now owns 201,177 shares of the biopharmaceutical company’s stock valued at $1,659,000 after buying an additional 28,492 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Corbus Pharmaceuticals Holdings by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,255,429 shares of the biopharmaceutical company’s stock valued at $10,357,000 after buying an additional 71,419 shares in the last quarter. Segantii Capital Management Ltd boosted its position in shares of Corbus Pharmaceuticals Holdings by 683.3% in the first quarter. Segantii Capital Management Ltd now owns 56,400 shares of the biopharmaceutical company’s stock valued at $465,000 after buying an additional 49,200 shares during the last quarter. Laurion Capital Management LP acquired a new position in shares of Corbus Pharmaceuticals Holdings during the first quarter valued at $1,015,000. Finally, IPG Investment Advisors LLC acquired a new position in shares of Corbus Pharmaceuticals Holdings during the first quarter valued at $109,000. Institutional investors own 28.06% of the company’s stock.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) opened at 6.55 on Thursday. Corbus Pharmaceuticals Holdings, Inc. has a 12 month low of $2.76 and a 12 month high of $10.78. The company’s market cap is $328.93 million. The company has a 50-day moving average of $6.34 and a 200 day moving average of $7.28.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.16). The business had revenue of $1.29 million for the quarter, compared to analysts’ expectations of $2.50 million. Corbus Pharmaceuticals Holdings had a negative net margin of 874.41% and a negative return on equity of 117.78%. On average, equities analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post ($0.77) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was reported by BBNS and is owned by of BBNS. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://baseballnewssource.com/markets/creative-planning-increases-position-in-corbus-pharmaceuticals-holdings-inc-crbp/1236241.html.

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald set a $24.00 price target on shares of Corbus Pharmaceuticals Holdings and gave the company a “buy” rating in a research report on Monday. BidaskClub raised shares of Corbus Pharmaceuticals Holdings from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. Noble Financial reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research report on Friday, June 16th. Finally, JMP Securities reaffirmed an “outperform” rating and issued a $27.00 price target (up previously from $20.00) on shares of Corbus Pharmaceuticals Holdings in a research report on Monday, April 3rd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $20.50.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Institutional Ownership by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Veteran Pitcher Bartolo Colon Considering Retirement
Veteran Pitcher Bartolo Colon Considering Retirement
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base


Leave a Reply

 
© 2006-2017 BBNS.